Holen Sie sich die Stockscreener-App
10.10
0.10%
-0.010
Schlusskurs vom Vortag:
$10.11
Offen:
$10.14
24-Stunden-Volumen:
1.40M
Relative Volume:
0.84
Marktkapitalisierung:
$446.47M
Einnahmen:
$127.70M
Nettoeinkommen (Verlust:
$-121.25M
KGV:
-3.2063
EPS:
-3.15
Netto-Cashflow:
$-120.32M
1W Leistung:
-0.10%
1M Leistung:
-1.85%
6M Leistung:
+38.55%
1J Leistung:
-30.34%
1-Tages-Spanne:
$10.10
$10.16
1-Wochen-Bereich:
$10.09
$10.16
52-Wochen-Spanne:
$4.80
$18.13
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Firmenname
Iteos Therapeutics Inc
Sektor
Branche
Telefon
857-204-4583
Adresse
321 ARSENAL STREET, WATERTOWN
Vergleichen Sie ITOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.10 | 446.92M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-05-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-13 | Eingeleitet | Wells Fargo | Overweight |
| 2021-05-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-18 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Iteos Therapeutics Inc Aktie (ITOS) Neueste Nachrichten
How iTeos Therapeutics Inc. stock performs during market volatilityFree Stock Market News Updates - mustnews.co.kr
GSK and iTeos Therapeutics’ Promising Phase 3 Lung Cancer Study: Market Implications - TipRanks
Iteos Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
iTeos Therapeutics Faces Challenges Amid Collaboration Termination - TipRanks
iTeos Therapeutics, Inc. SEC 10-Q Report - TradingView
iTeos Therapeutics (ITOS.US) Boxer Capital, LLC sold 350,000 common shares worth approximately US$5.6927 million - 富途牛牛
iTeos Therapeutics Inc. Approaches Support With Recovery in SightAlpha Driven Watchlist With Alerts Published - metal.it
iTeos Therapeutics Inc. Stock Poised for Technical ComebackFree Investment Portfolio Suggestions - beatles.ru
What makes iTeos Therapeutics Inc. stock price move sharplyDiscover undervalued opportunities early - Jammu Links News
What is iTeos Therapeutics Inc. company’s growth strategyGrow your portfolio with growth-oriented stocks - Jammu Links News
Is iTeos Therapeutics Inc. a growth stock or a value stockDiscover undervalued stocks ready to soar - Jammu Links News
What is the dividend policy of iTeos Therapeutics Inc. stockAchieve consistent double-digit returns - Jammu Links News
What catalysts could drive iTeos Therapeutics Inc. stock higher in 2025Build capital through low-risk investments - Jammu Links News
Is iTeos Therapeutics Inc. stock overvalued or undervaluedAchieve breakthrough results with expert guidance - Jammu Links News
How volatile is iTeos Therapeutics Inc. stock compared to the marketCapitalize on emerging investment opportunities - Jammu Links News
Price momentum metrics for iTeos Therapeutics Inc. explainedDaily Technical Forecast for Quick Gains - Newser
What are the technical indicators suggesting about iTeos Therapeutics Inc.Wealth Building Planner With Proven Results - Jammu Links News
Halper Sadeh Investigates iTeos Therapeutics, Veritex Holdings Merger Deals. - AInvest
Why iTeos Therapeutics Inc. stock attracts strong analyst attentionTrade Timing Strategy With Technical Data Explained - metal.it
Investigations into OLO, VBTX, ITOS, and WNS Shareholder Rights - AInvest
Reddit Investors Lose Big, Now Have Opportunity to Lead Fraud Lawsuit - AInvest
iTeos Therapeutics acquisition by Concentra Biosciences raises fiduciary duty concerns. - AInvest
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Visual trend scoring systems applied to iTeos Therapeutics Inc.Alpha Driven Watchlist With Alerts Published - metal.it
iTeos Therapeutics Inc. Added to High Probability Setup ListTriple Return Setup With Risk Control Explained - metal.it
These 10 Stocks are Winning Big - Insider Monkey
Is iTeos Therapeutics Inc. stock poised for growthReliable Investment Entry Signals Confirmed by Charts - metal.it
Using data tools to time your iTeos Therapeutics Inc. exitFree Early Entry Picks Before News Breakout - Newser
Can momentum traders help lift iTeos Therapeutics Inc.Trade Setup Builder with Custom Alerts - Newser
Price momentum metrics for iTeos Therapeutics Inc. explained Long-Term Safety Investment Analysis Report - Newser
How strong is iTeos Therapeutics Inc. company’s balance sheetInvest smarter with expert trading signals - Jammu Links News
Published on: 2025-07-27 21:40:11 - Jammu Links News
How Efficient Is iTeos Therapeutics Inc. at Controlling Operating CostsFree Deep Market Trend Analysis - Newser
Key External Factors That Drive iTeos Therapeutics Inc. Stock Price MovementsDaily Breakout Picks - Newser
Will iTeos Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsCapital Growth Picks - Newser
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, CIO, SNV on Behalf of Shareholders - GlobeNewswire Inc.
Wedbush Research Analysts Cut Earnings Estimates for ITOS - Defense World
Finanzdaten der Iteos Therapeutics Inc-Aktie (ITOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):